All Updates

All Updates

icon
Filter
Funding
Identifai-Genetics raises USD 3.3 million in post-seed funding round
Precision Medicine
Apr 18, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Apr 18, 2023

Identifai-Genetics raises USD 3.3 million in post-seed funding round

Funding

  • Tel Aviv-based genetic testing company Identifai-Genetics has raised USD 3.3 million in a post-seed funding round led by eHealth Ventures and included participation from Dr. Ron Sabar, founder and CMO of Sabar Health, among others. The company claims to have raised over USD 6 million in equity investments and R&D grants. The planned uses of the funds were not disclosed.

  • Identifai Genetics is focused on developing a liquid biopsy test that uses maternal blood samples for the non-invasive detection of fetal genetic disorders at an early stage of pregnancy. The company claims to offer the only available clinical solution for an early, non-invasive prenatal genetic screening, from point mutations to chromosomal anomalies. By identifying severe genetic disorders with high accuracy, Identifai-Genetics aims to help mitigate the risk of amniocentesis and placental cysts. The company is planning to launch clinical studies to further validate its technology.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.